Cryopyrin-associated periodic syndromes (CAPS) are a group of rare genetic disorders characterized by recurrent episodes of inflammation. These syndromes are caused by mutations in the NLRP3 gene, which is responsible for producing cryopyrin protein. CAPS encompasses three distinct conditions: familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and neonatal-onset multisystem inflammatory disease (NOMID) or chronic infantile neurologic cutaneous and articular syndrome (CINCA).
Diagnosis of CAPS is based on clinical symptoms, family history, and genetic testing. Early detection is crucial to prevent long-term complications. Treatment options for CAPS aim to control inflammation and manage symptoms. These may include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and interleukin-1 (IL-1) inhibitors.
While the exact prevalence of CAPS is unknown, it is considered an extremely rare condition. Genetic inheritance patterns play a role in the occurrence of CAPS, with most cases being inherited in an autosomal dominant manner.
Research into CAPS is ongoing, with scientists continuously striving to improve our understanding of the underlying mechanisms and develop more effective treatments. By raising awareness and supporting research efforts, we can contribute to better outcomes for individuals living with CAPS.
Cryopyrin-associated periodic syndromes (CAPS) are a group of rare autoinflammatory disorders characterized by recurrent fever episodes, skin rashes, joint pain, and other symptoms. While there is no cure for CAPS, several treatment options are available to manage the condition and improve the quality of life for affecte...
To see full information about treatment please Sign up or Log in